Willow
Women-focused compounded GLP-1 telehealth brand operating in a limited number of states, tied to a National Advertising Division referral over its marketing claims.
What we like
What to watch
Full Review
Willow positions itself as a women-focused alternative to general GLP-1 telehealth brands, bundling compounded semaglutide or tirzepatide with unlimited doctor access starting at $299/mo. Its footprint is narrow — reportedly around a dozen states — well short of most national competitors, and the company was reportedly referred by the National Advertising Division to state attorneys general in December 2025 over its advertising claims, a meaningful reputational and regulatory flag. Reviewers describe responsive, board-certified doctors and a straightforward process, though its review base (354 on Trustpilot) is thin relative to category leaders, and some patients report the oral formulation underperforming the injectable version.
Last researched: 2026-09-19
Pricing
Prices shown are based on our most recent research and may not reflect current pricing. Telehealth providers update their pricing frequently. Always verify pricing directly with the provider before purchasing.
| Treatment | Category | Price/mo | Includes | Notes |
|---|---|---|---|---|
| Compounded Semaglutide | Weight Loss / GLP-1 | $299 | ● Consults○ Lab work● Shipping | Subscription required |
| Compounded Tirzepatide | Weight Loss / GLP-1 | $399 | ● Consults○ Lab work● Shipping | Subscription required |